Jiangsu Hengrui Pharmaceuticals Co., Ltd. and IDEAYA Biosciences, Inc. are set to showcase their groundbreaking research at the IASLC 2025 World Conference on Lung Cancer (WCLC), scheduled to take place from September 6-9, 2025, in Barcelona, Spain. The two companies will present their oral and poster presentations focusing on IDE849 (SHR-4849), an innovative DLL3-targeting antibody drug conjugate (ADC) that has shown promising results in treating small cell lung cancer (SCLC).

Highlighting the Safety and Efficacy of IDE849 (SHR-4849)
Hengrui and IDEAYA’s oral presentation will cover the safety and efficacy results from a Phase 1 trial of IDE849 (SHR-4849), a cutting-edge ADC developed to target DLL3, a protein that has been associated with several solid tumors. The trial, conducted in China, showcased the potential of this drug to address the unmet needs in cancers like melanoma, non-small cell lung cancer (NSCLC), and neuroendocrine tumors (NETs).

The oral presentation, titled “A First-in-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody Drug Conjugate (ADC) in Relapsed SCLC,” will take place on Sunday, September 7, 2025, from 4:45 to 6:00 PM CET, as part of Session OA6 Novel ADCs in SCLC.

Innovative Research on Dual PARG-TOP1 Inhibition
Additionally, IDEAYA will present a poster detailing its research on the combination of PARG and TOP1 inhibition, a novel strategy for enhancing the effectiveness of ADCs like IDE849 and IDE034. The poster, titled “Dual PARG-TOP1 Inhibition Exacerbates DNA-Protein Crosslinks and Replication Stress: A Promising Strategy for Enhancing TOP1i-ADC Efficacy,” will be presented by Reeja Maskey, Ph.D., on Monday, September 8, 2025, from 10:30 AM to 12:00 PM CET, in Session P2.10 Metastatic NSCLC, Antibody Drug Conjugates, and Cytotoxic Therapy.

Presentation Availability
Both the oral and poster presentations will be available online at IDEAYA’s Investor Relations.

Statements from Company Leaders
Dr. Darrin Beaupre, Chief Medical Officer at IDEAYA Biosciences, expressed his pride in the collaboration with Hengrui: “We are excited to present the first-in-human Phase 1 clinical safety and efficacy data for IDE849 (SHR-4849) at WCLC 2025. This marks an important milestone in advancing the global development of IDE849 as a potential treatment for SCLC.”

The IASLC 2025 conference represents a pivotal moment for the advancement of lung cancer research, and the collaborative efforts between Hengrui and IDEAYA Biosciences will bring cutting-edge treatments one step closer to patients in need.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com